Americana Partners LLC Sells 1,901 Shares of Johnson & Johnson $JNJ

Americana Partners LLC decreased its position in Johnson & Johnson (NYSE:JNJ) by 1.0% in the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 184,964 shares of the company’s stock after selling 1,901 shares during the period. Johnson & Johnson accounts for about 1.0% of Americana Partners LLC’s investment portfolio, making the stock its 27th biggest position. Americana Partners LLC’s holdings in Johnson & Johnson were worth $28,253,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Brighton Jones LLC grew its holdings in Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after acquiring an additional 6,332 shares in the last quarter. Wealth Group Ltd. purchased a new stake in shares of Johnson & Johnson in the 1st quarter worth approximately $218,000. Smart Money Group LLC boosted its stake in shares of Johnson & Johnson by 6.5% during the first quarter. Smart Money Group LLC now owns 6,687 shares of the company’s stock valued at $1,109,000 after purchasing an additional 407 shares in the last quarter. Diversify Wealth Management LLC increased its holdings in Johnson & Johnson by 16.8% during the first quarter. Diversify Wealth Management LLC now owns 23,008 shares of the company’s stock valued at $3,587,000 after buying an additional 3,317 shares during the period. Finally, Gateway Wealth Partners LLC increased its holdings in Johnson & Johnson by 17.4% during the first quarter. Gateway Wealth Partners LLC now owns 2,729 shares of the company’s stock valued at $453,000 after buying an additional 404 shares during the period. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Down 0.3%

Shares of Johnson & Johnson stock opened at $186.50 on Monday. The firm’s 50 day simple moving average is $184.25 and its two-hundred day simple moving average is $168.80. The firm has a market capitalization of $449.34 billion, a price-to-earnings ratio of 18.00, a PEG ratio of 2.19 and a beta of 0.38. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $194.48. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The business had revenue of $24.02 billion during the quarter. Analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.8%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 50.19%.

Insider Activity at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.16% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

JNJ has been the topic of several recent research reports. JPMorgan Chase & Co. increased their target price on Johnson & Johnson from $185.00 to $200.00 and gave the company a “neutral” rating in a research report on Tuesday, September 16th. UBS Group raised their price objective on Johnson & Johnson from $190.00 to $214.00 and gave the company a “buy” rating in a research report on Tuesday, October 14th. Sanford C. Bernstein lifted their target price on Johnson & Johnson from $172.00 to $193.00 and gave the company a “market perform” rating in a research note on Monday, October 6th. Erste Group Bank raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Wednesday, July 23rd. Finally, Daiwa America raised shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 20th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $199.05.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.